Understanding how a protein complex affects gene silencing related to sickle cell disease
The role of the MBD2-NuRD complex in gamma-globin gene silencing
This study is looking at a special protein complex that helps control blood gene activity, with the hope of finding new ways to boost healthy hemoglobin levels in adults with sickle cell disease and beta-thalassemia, ultimately aiming to create safer treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10442549 on NIH RePORTER |
What this research studies
This research investigates the MBD2-NuRD complex, which plays a crucial role in regulating the expression of globin genes, particularly in the context of sickle cell disease and beta-thalassemia. By examining how this protein complex interacts with specific genes, the researchers aim to identify potential therapeutic targets that could activate fetal hemoglobin expression in adults. The study employs advanced techniques such as genome editing and structural analysis to explore these interactions in adult human erythroid cells. The ultimate goal is to develop safe therapies that could improve outcomes for patients with these blood disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with sickle cell disease or beta-thalassemia.
Not a fit: Patients with other forms of anemia or blood disorders unrelated to sickle cell disease or beta-thalassemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, potentially alleviating symptoms and complications.
How similar studies have performed: Previous research has shown promise in targeting similar epigenetic mechanisms to treat blood disorders, indicating that this approach could be viable.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Ginder, Gordon D — Virginia Commonwealth University
- Study coordinator: Ginder, Gordon D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.